FC
KERX

Finepoint Capital’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Finepoint Capital’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,605,800
Closed -$16M – 9
2015
Q2 		$16M Hold
1,605,800
– – 4.65% 7
2015
Q1 		$20.4M Buy
+1,605,800
New +$20.6M 6.86% 5

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

Finepoint Capital's KERX Position: Q3 2015 in Review

Finepoint Capital sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2015, closing a stake of 1,605,800 shares — an estimated $16M sold.

Finepoint Capital first reported a position in KERX in Q1 2015 and held it in 2 quarters. The position peaked at $20.4M in Q1 2015. 138 funds tracked by Wall St. Rank hold KERX as of Q3 2015.

  • Finepoint Capital reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2015 after selling out during the quarter.
  • Finepoint Capital sold 1,605,800 Keryx Biopharmaceuticals Inc shares in Q3 2015, an estimated $16M.
  • Finepoint Capital first reported a position in Keryx Biopharmaceuticals Inc in Q1 2015 and held it in 2 quarters.
  • Finepoint Capital's Keryx Biopharmaceuticals Inc position peaked at $20.4M in Q1 2015.
  • 138 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2015.

Based on Finepoint Capital's 13F filing for Q3 2015, filed 13 Nov 2015.